Search - tctmd.com

Displaying 221 - 240 of 249

Sort: Relevancy | Date

Presentation TCT 2012

Proposals for New Short-Term DAPT Use Trials After DES

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

Continuity Equation: Streamlining Processes from Pre-Market Approval to Post-Market Surveillance

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

Factor IXa Inhibition (Aptamer) Update

Presenter: Roxana Mehran

October 24, 2012

Presentation TCT 2012

A View to Future Trials: HORIZONS-AMI II and Others

Presenter: Roxana Mehran

October 24, 2012

Presentation TCT 2012

Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores?

Presenter: Roxana Mehran

October 23, 2012

Presentation TCT 2012

In-Stent Restenosis: Mechanisms, Predictors, and Treatment

Presenter: Roxana Mehran

October 23, 2012

Presentation TCT 2012

Chronic Kidney Disease, Contrast Agents, and Radiocontrast Nephropathy

Presenter: Roxana Mehran

October 23, 2012

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

Dedicated Bifurcation Stents: Minvasys Nile Program Update

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

Choice of Antiplatelet Therapies in ACS/STEMI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

US Perspective

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

Randomized Trials vs. Observational Studies: Advantages and Pitfalls

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

Contrast-Induced Nephrotoxicity

Presenter: Roxana Mehran

October 22, 2012

Presentation SCAI 2012

Left Main/Multivessel PCI v. CABG: Where Are They Today?

Presenter: Roxana Mehran

May 09, 2012

Presentation Fellows 2012

Oral Antiplatelet Agents in PCI and ACS

Presenter: Roxana Mehran

April 22, 2012

Presentation PCI Outcomes 2012

Case 3: A Patient with Recurrent Stent Thrombosis

Presenter: Roxana Mehran

March 23, 2012

Presentation CIT 2012

How to start and set up a Research Program? The Basic Tools

Presenter: Roxana Mehran

March 15, 2012

Presentation TCT 2012

Use of the REG1 Anticoagulation System During PCI May Improve Bleeding and Ischemic Complications Compared with Heparin: A PCI Substudy from the Phase 2B RADAR Trial

Presenter: Thomas J. Povsic, John P. Vavalle, Laura H. Aberle, Steven L. Zelenkofske, Roxana Mehran, Mauricio G. Cohen, Christopher E. Buller, Jan H. Cornel, Jaroslaw D. Kasprzak, Gilles Montalescot, Peter Fail, Ian J. Sarembock, John H. Alexander

January 03, 2012

Presentation TCT 2012

The Utility of Three Primary Prevention Scoring Systems (Framingham, PROCAM, and SCORE) in Predicting Future Events in Patients with Acute Coronary Syndromes: The PROSPECT Trial

Presenter: Jung-Won Suh, Gary S. Mintz, Giora Weisz, Akiko Maehara, Ke Xu, Alexandra J. Lansky, Ecaterina Cristea, Roxana Mehran, John McPherson, Naim Farhat, Steven P. Marso, Bernard de Bruyne, Patrick W. Serruys, Gregg W. Stone

January 03, 2012

Advertisement

Proposals for New Short-Term DAPT Use Trials After DES

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Continuity Equation: Streamlining Processes from Pre-Market Approval to Post-Market Surveillance

Factor IXa Inhibition (Aptamer) Update

A View to Future Trials: HORIZONS-AMI II and Others

Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores?

In-Stent Restenosis: Mechanisms, Predictors, and Treatment

Chronic Kidney Disease, Contrast Agents, and Radiocontrast Nephropathy

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Dedicated Bifurcation Stents: Minvasys Nile Program Update

Choice of Antiplatelet Therapies in ACS/STEMI

US Perspective

Randomized Trials vs. Observational Studies: Advantages and Pitfalls

Contrast-Induced Nephrotoxicity

Left Main/Multivessel PCI v. CABG: Where Are They Today?

Oral Antiplatelet Agents in PCI and ACS

Case 3: A Patient with Recurrent Stent Thrombosis

How to start and set up a Research Program? The Basic Tools

Use of the REG1 Anticoagulation System During PCI May Improve Bleeding and Ischemic Complications Compared with Heparin: A PCI Substudy from the Phase 2B RADAR Trial

The Utility of Three Primary Prevention Scoring Systems (Framingham, PROCAM, and SCORE) in Predicting Future Events in Patients with Acute Coronary Syndromes: The PROSPECT Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content